Sandra Rogers
Nurse Practitioner · Frisco, TXNPI 1710423017
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 413 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 27.8% of the total. 2025 is the largest year on record at $2,012, 3.5 times the $573 reported in 2021. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 413 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Lilly USA, LLC$645
- Corcept Therapeutics$467
- AstraZeneca$431
- Antares Pharma, Inc.$358
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,877100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 154 | $2,193 |
| Novo Nordisk | 48 | $1,145 |
| Lilly USA, LLC | 27 | $645 |
| Corcept Therapeutics | 12 | $467 |
| AstraZeneca | 13 | $431 |
| Antares Pharma, Inc. | 20 | $358 |
| Pfizer | 32 | $356 |
| Exact Sciences | 9 | $280 |
| Bayer | 10 | $235 |
| Boehringer Ingelheim | 11 | $198 |
| Dexcom, Inc. | 6 | $171 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $163 |
| Noven Therapeutics, LLC | 8 | $157 |
| Amgen(2 entities) | 3 | $143 |
| Abbott | 3 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Tris Pharma Inc | 3 | $75 |
| Halozyme Inc | 4 | $73 |
| Currax Pharmaceuticals LLC | 4 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $63 |
| Astellas Pharma US Inc | 4 | $62 |
| Mannkind Corporation | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Corium, LLC | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Eisai Inc. | 1 | $24 |
| Medtronic | 1 | $20 |
| Intra-sana Laboratories | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Linus Health, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Vivus LLC | 1 | $15 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,877 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $39,314 |
| MounjaroTirzepatide | 24 | $24,481 |
| Duloxetine Hcl | 25 | $495 |
| Levothyroxine Sodium | 49 | $393 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 13 | $138 |
| Rosuvastatin Calcium | 22 | $102 |
| Amlodipine Besylate | 16 | $69 |
| Pantoprazole Sodium | 18 | $66 |
| Lisinopril | 12 | $64 |
| Methocarbamol | 11 | $51 |
| Famotidine | 12 | $23 |
| Furosemide | 12 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,145 | $39,31443 claims |
| Lilly USA, LLCMounjaro | $645 | $24,48124 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $39349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Frisco
- Dena MillerFrisco$36K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Onna FeuchterSouthlake$108K
- Stephanie AgrellaRound Rock$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.